Open Access

Advances in in silico drug discovery for rabies virus: Innovations in ligand identification and therapeutic mechanisms (Review)

  • Authors:
    • Rakshana Rangaraj
    • Swetha Sunkar
  • View Affiliations

  • Published online on: July 17, 2025     https://doi.org/10.3892/wasj.2025.378
  • Article Number: 90
  • Copyright : © Rangaraj et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Rabies remains a nearly universally fatal zoonotic disease once clinical symptoms manifest, despite the availability of effective vaccines. The lack of viable therapeutic interventions post‑symptom onset has fueled the exploration of novel strategies, particularly computational approaches. The present review highlights recent advancements in in silico drug discovery targeting rabies virus, focusing on structure‑based drug design, ligand screening, molecular dynamics and artificial intelligence‑assisted repurposing. Specific viral proteins, including nucleoprotein (N), glycoprotein (G) and RNA‑dependent RNA polymerase (L), have been computationally analyzed as promising therapeutic targets. Several FDA‑approved drugs, such as emtricitabine and micafungin, along with phytochemicals such as (+)‑catechin, have demonstrated strong binding affinities in docking simulations. Additionally, the development of multi‑epitope peptide vaccines and RNA‑based platforms, including mRNA vaccines and RNA interference, provides innovative preventive strategies. The integration of bioinformatics tools, such as AlphaFold, IEDB, CB‑Dock2 and PLIP has streamlined target identification and validation. Despite notable computational progress, translational gaps remain due to limited experimental validation. The present review emphasizes the importance of combining in silico predictions with laboratory research and clinical data to accelerate the development of effective rabies therapies. With an increasing global health burden, particularly in resource‑limited regions, computational drug discovery holds promise for bridging critical treatment gaps in rabies management.
View Figures
View References

Related Articles

Journal Cover

September-October 2025
Volume 7 Issue 5

Print ISSN: 2632-2900
Online ISSN:2632-2919

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Rangaraj R and Sunkar S: Advances in <em>in silico</em> drug discovery for rabies virus: Innovations in ligand identification and therapeutic mechanisms (Review). World Acad Sci J 7: 90, 2025.
APA
Rangaraj, R., & Sunkar, S. (2025). Advances in <em>in silico</em> drug discovery for rabies virus: Innovations in ligand identification and therapeutic mechanisms (Review). World Academy of Sciences Journal, 7, 90. https://doi.org/10.3892/wasj.2025.378
MLA
Rangaraj, R., Sunkar, S."Advances in <em>in silico</em> drug discovery for rabies virus: Innovations in ligand identification and therapeutic mechanisms (Review)". World Academy of Sciences Journal 7.5 (2025): 90.
Chicago
Rangaraj, R., Sunkar, S."Advances in <em>in silico</em> drug discovery for rabies virus: Innovations in ligand identification and therapeutic mechanisms (Review)". World Academy of Sciences Journal 7, no. 5 (2025): 90. https://doi.org/10.3892/wasj.2025.378